| pubmed-article:10360656 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10360656 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10360656 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:10360656 | lifeskim:mentions | umls-concept:C0015980 | lld:lifeskim |
| pubmed-article:10360656 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:10360656 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:10360656 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:10360656 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:10360656 | pubmed:issue | 5-6 | lld:pubmed |
| pubmed-article:10360656 | pubmed:dateCreated | 1999-6-23 | lld:pubmed |
| pubmed-article:10360656 | pubmed:abstractText | This study compared the efficacy and safety of 5-fluorouracil (5-FU) monotherapy to that of 5-FU combined with natural human interferon-beta (IFN-beta) in patients with unresectable, advanced colorectal carcinoma. Forty-nine chemotherapy-naive patients were randomized to 5-FU alone or to the combination. All patients received 750 mg m(-2) day(-1) 5-FU for 5 days by continuous intravenous (i.v.) infusion, followed after day 15 by a weekly i.v. bolus of 750 mg m(-2). IFN-beta was injected intramuscularly three times weekly at 9 M IU. Treatment continued for 52 weeks, or until disease progression or intolerable toxicity. Clinical endpoints were tumor response, time to progression, survival and toxicity. The addition of IFN-3 to 5-FU significantly improved response rate (33.3% vs 4.5% for evaluable patients; P = 0.021), time to progression (median 7.2 vs 4.2 months; P = 0.0435), and survival time (median 15.9 vs 7.2 months; P = 0.038) without significantly increasing toxicity compared to 5-FU alone. Cumulative 5-FU dose was higher with combined therapy (P < 0.001): more patients receiving monotherapy discontinued treatment because of disease progression. Fever was more frequent with combined therapy (P = 0.008); there were no other differences in toxicity. The only grade IV toxicity observed was neutropenia (two patients per group). A randomized phase III trial has been initiated to confirm the synergy between 5-FU and IFN-beta. | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10360656 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10360656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10360656 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10360656 | pubmed:month | May | lld:pubmed |
| pubmed-article:10360656 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:10360656 | pubmed:author | pubmed-author:MassutiBB | lld:pubmed |
| pubmed-article:10360656 | pubmed:author | pubmed-author:SánchezBB | lld:pubmed |
| pubmed-article:10360656 | pubmed:author | pubmed-author:CandelM TMT | lld:pubmed |
| pubmed-article:10360656 | pubmed:author | pubmed-author:Villar-Grimal... | lld:pubmed |
| pubmed-article:10360656 | pubmed:author | pubmed-author:FrayEE | lld:pubmed |
| pubmed-article:10360656 | pubmed:author | pubmed-author:LizónJJ | lld:pubmed |
| pubmed-article:10360656 | pubmed:author | pubmed-author:GoedkoopRR | lld:pubmed |
| pubmed-article:10360656 | pubmed:author | pubmed-author:GorostidiBB | lld:pubmed |
| pubmed-article:10360656 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10360656 | pubmed:volume | 80 | lld:pubmed |
| pubmed-article:10360656 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10360656 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10360656 | pubmed:pagination | 786-91 | lld:pubmed |
| pubmed-article:10360656 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:meshHeading | pubmed-meshheading:10360656... | lld:pubmed |
| pubmed-article:10360656 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10360656 | pubmed:articleTitle | A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer. | lld:pubmed |
| pubmed-article:10360656 | pubmed:affiliation | H. Arnau de Vilanova, Valencia, Spain. | lld:pubmed |
| pubmed-article:10360656 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10360656 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10360656 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10360656 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10360656 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:10360656 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10360656 | lld:pubmed |
